Navigation Links
Biodel to Report First Quarter Fiscal Year 2012 Financial Results on February 8, 2012
Date:2/3/2012

DANBURY, Conn., Feb. 3, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its first quarter fiscal year 2012 financial results on February 8, 2012.  Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress. 

February 8, 2012 schedule: 

 4:00 pm EST:

1Q fiscal year 2012 results will be distributed 

 4:15 pm EST:

Conference call participants should dial: 

+1 ( 877 ) 303 - 8028  (United States) or 

+1 ( 760 ) 536 - 5167  (International) 

  

 4:30 pm EST:

Conference call begins 

  

 Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at www.biodel.com.  The audio webcast will be archived and available for replay through the website.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients.  We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.  For further information regarding Biodel, please visit the company's website at www.biodel.com.

BIOD-G

Contact: Seth D. Lewis, +1-646-378-2952

 

 


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biodel Announces Name Change for Lead Product Candidate
2. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
3. Biodel to Raise $30 Million Through Registered Direct Offering
4. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
5. Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
6. BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
7. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
8. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
9. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
10. Par Pharmaceutical Reports Second Quarter 2008 Results
11. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... ... of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with ... strains genetically engineered to express human antibodies. The partnership will use GigaGen technology ...
(Date:2/28/2017)... , Feb. 28, 2017  ITL Limited ... company, supplier and strategic partner that provides innovative ... individual health management, formally announces its rebrand to ... name change is part of the Company,s unified ... launch of an integrated corporate website, ITLHealthGroup.com ...
(Date:2/28/2017)... and NEW YORK , February ... License Application accepted by the FDA for avelumab  ... disease has metastasized   ... Germany , in the US and ... US Food and Drug Administration (FDA) has accepted for Priority ...
(Date:2/27/2017)... -- A Europe-wide survey of institutes conducted by the ... their research treat them with due care. The survey polled a ... the results indicates that there is a strong commitment among animal ... the principles of the 3Rs (Refine, Reduce, Replace)  ... What are the 3Rs? ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
Breaking Biology News(10 mins):